Malaysia’s leading pharmaceutical company Duopharma Biotech has signed a Distribution Agreement to scale iBreastExam in Malaysia with US-based women’s health innovator company, UE LifeSciences Inc.’s Malaysian wholly-owned subsidiary UE LifeSciences Sdn Bhd.

The collaboration is set to launch and scale the iBreastExam across Malaysia, a breakthrough innovation for radiation-free, clinically effective and accessible breast cancer early detection for women of all ages and demographics.

Under the distribution partnership, UE LifeSciences and Duopharma Biotech plan to collaborate with private and governmental healthcare sectors by making iBreastExam available at primary-care clinics across Malaysia to bridge the lack of access to early detection.

The collaboration will empower frontline healthcare providers with the mobile tools to drive preliminary screening in the community, where women live and work. The device is designed for use by frontline health workers, nurses, primary care providers and NGOs operating in the women’s health areas. It is quick, user friendly and requires minimal training.

Breast lumps are stiffer than normal breast tissue. iBreastExam incorporates Dynamic Co-Planar Capacitive (DCPC) Sensor Technology that measures the differences in tissue elasticity, in real-time, at the point of care and without requiring manual interpretation. It helps in identifying and triaging for clinically relevant breast lumps in healthy, asymptomatic women.